DNPUF Stock Chart & Stats
$9.14
$0.00(0.00%)
At close: 4:00 PM EDT
$9.14
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$7.31 - $19.92
Previous CloseN/A
Volume20.00
Average Volume (3M)36.00
Market Cap
$5.36B
Enterprise Value$791.57B
Total Cash (Recent Filing)$76.64B
Total Debt (Recent Filing)$160.66B
Price to Earnings (P/E)6.7
Beta0.46
Next Earnings
Jan 29, 2027EPS Estimate
0.69Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)279.80
Shares Outstanding449,204,560
10 Day Avg. Volume108
30 Day Avg. Volume36
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.82
Price to Sales (P/S)1.82
P/FCF Ratio12.29
Enterprise Value/Market Cap147.55
Enterprise Value/Revenue1.67
Enterprise Value/Gross Profit3.03
Enterprise Value/Ebitda6.00
Forecast
1Y Price Target
$17.13Price Target Upside87.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.39
Revenue Forecast (FY)$3.59B
Bulls Say, Bears Say
Bulls Say
Strong Profitability ReboundThe sharp return to strong gross, operating, EBITDA, and net margins improves the company’s ability to fund research, commercialization, and debt reduction internally. If this profitability is sustained, it provides a stronger base for earnings resilience and future investment than the loss-making periods.
Positive Cash GenerationPositive free cash flow that closely tracks reported earnings indicates the current profit recovery is reasonably supported by cash rather than accounting results alone. This strengthens internal funding capacity for operations and investment while providing a useful buffer against financing pressure.
Improved LeverageThe reduction in debt-to-equity and rebuilding of equity represent a meaningful improvement in financial flexibility. A less leveraged balance sheet can reduce stress on future cash flows, support continued investment in the pharmaceutical portfolio, and improve the company’s ability to withstand uneven operating results.
Bears Say
Earnings VolatilityThe shift from deep losses in 2023–2024 to high TTM profitability demonstrates that earnings power has not been stable across the cycle. Such volatility makes it harder to assess the durability of current margins and can constrain consistent planning, investment, and shareholder returns.
Weak Debt-service CoverageAlthough free cash flow is currently positive, operating cash flow covers only a modest portion of debt, limiting near-term debt-paying capacity from recurring operations alone. This leaves the company more exposed if profitability weakens or cash conversion deteriorates before leverage can decline further.
Cash-flow DeteriorationNegative TTM free-cash-flow growth and the prior period of severe cash burn indicate that current cash generation may not yet represent a consistently expanding trend. Continued volatility could reduce funds available for research, launches, debt reduction, and other long-term capital priorities.
Sumitomo Dainippon Pharma Co News
DNPUF FAQ
What was Sumitomo Dainippon Pharma Co Ltd’s price range in the past 12 months?
Sumitomo Dainippon Pharma Co Ltd lowest stock price was $7.31 and its highest was $19.92 in the past 12 months.
What is Sumitomo Dainippon Pharma Co Ltd’s market cap?
Sumitomo Dainippon Pharma Co Ltd’s market cap is $5.36B.
When is Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date?
Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date is Jan 29, 2027 which is in 89 days.
How were Sumitomo Dainippon Pharma Co Ltd’s earnings last quarter?
Sumitomo Dainippon Pharma Co Ltd released its earnings results on Oct 30, 2026. The company reported $0.301 earnings per share for the quarter, beating the consensus estimate of $0.179 by $0.122.
Is Sumitomo Dainippon Pharma Co Ltd overvalued?
According to Wall Street analysts Sumitomo Dainippon Pharma Co Ltd’s price is currently Undervalued.
Does Sumitomo Dainippon Pharma Co Ltd pay dividends?
Sumitomo Dainippon Pharma Co Ltd pays a Notavailable dividend of $0.095 which represents an annual dividend yield of 0.8%. See more information on Sumitomo Dainippon Pharma Co Ltd dividends here
What is Sumitomo Dainippon Pharma Co Ltd’s EPS estimate?
Sumitomo Dainippon Pharma Co Ltd’s EPS estimate is 0.69.
How many shares outstanding does Sumitomo Dainippon Pharma Co Ltd have?
Sumitomo Dainippon Pharma Co Ltd has 449,204,560 shares outstanding.
What happened to Sumitomo Dainippon Pharma Co Ltd’s price movement after its last earnings report?
Sumitomo Dainippon Pharma Co Ltd reported an EPS of $0.301 in its last earnings report, beating expectations of $0.179. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sumitomo Dainippon Pharma Co Ltd?
Currently, no hedge funds are holding shares in DNPUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
DNPUF Company Deck
DNPUF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted promising developments in the oncology and regenerative medicine pipelines but was overshadowed by significant financial losses, decreased revenue across all segments, and underperformance of key products, leading to a revised downward financial forecast. The call focused on strategic adjustments to address market challenges and improve profitability.View all DNPUF earnings summariesDNPUF Stock 12 Month Forecast
Average Price Target
$17.13
▲(87.46% Upside)
Technical Analysis
Eisai Co
―
Kissei Pharmaceutical Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Nippon Shinyaku Co., Ltd.
―
Ownership Overview
―
Insiders
2.20% Mutual Funds
― Other Institutional Investors
93.86% Public Companies and
Individual Investors